Table 2.
Risdiplam treatment details
| Safety analysis set (N = 538) | |
|---|---|
| Daily dose of risdiplam (mg) | |
| Mean ± SD | 4.8 ± 0.6 |
| Median (min–max) | 5 (1.1–5.8) |
| Total risdiplam dose (mg) | |
| Mean ± SD | 2267.6 ± 1108.0 |
| Median (min–max) | 1830 (5–4605) |
| Total treatment duration (days) | |
| Mean ± SD | 472.0 ± 217.3 |
| Median (min–max) | 366 (1–921) |
| Administration status, n (%) | |
| Ongoing | 463 (86.1) |
| Discontinued | 69 (12.8) |
| Terminated | 6 (1.1) |
| Reason for discontinuation, n (%) | |
| Adverse events | 12 (2.2) |
| Insufficient efficacy | 15 (2.8) |
| No visit | 0 |
| Patient convenience | 7 (1.3) |
| Hospital transfer | 29 (5.4) |
| Death | 3 (0.6) |
| Other | 3 (0.6) |
| Unknown | 0 |
Total treatment duration=period during which the drug is administered (date of the last dose − date of the first dose)
max maximum, min minimum, SD standard deviation